ginsenoside-rh4 and Multiple-Myeloma

ginsenoside-rh4 has been researched along with Multiple-Myeloma* in 1 studies

Other Studies

1 other study(ies) available for ginsenoside-rh4 and Multiple-Myeloma

ArticleYear
Ginsenoside Rh4 inhibits the malignant progression of multiple myeloma and induces ferroptosis by regulating SIRT2.
    Clinical and experimental pharmacology & physiology, 2023, Volume: 50, Issue:9

    Multiple myeloma (MM) has a high mortality rate, and the exploration of therapeutic drugs for MM with low side effects is a hot topic at the moment. Ginsenoside Rh4 has been shown to inhibit tumour growth in many cancers. However, the role of ginsenoside Rh4 in MM and its reaction mechanism have not been reported so far. After the treatment with different concentrations of ginsenoside Rh4, the proliferation of NCI-H929 cells was detected by Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine staining. The cell apoptosis and cycle arrest were detected by flow cytometry and western blot. The thiobarbituric acid-reactive substances (TBARS) production was assessed with TBARS assay, whereas Fe

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferroptosis; Humans; Molecular Docking Simulation; Multiple Myeloma; Sirtuin 2; Thiobarbituric Acid Reactive Substances

2023